Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Overview of Diabetes, Management, and Pharmacotherapy Updates a Review


Affiliations
1 Department of Pharmacology, Jamia Hamdard University, New Delhi, India
2 Universiti Sultan Zainal Abidin, Gong Badak Campus, Kuala Terengganu, Malaysia
3 Department of Biochemistry, Usmanu Danfodio University, Sokoto, Nigeria
4 Universiti Sultan Zainal Abidin, Kota Campus, Kuala Terengganu, Malaysia
     

   Subscribe/Renew Journal


Diabetes mellitus (DM) is disease of global concern. There were almost 4000 million diabetic people in 2013, and they number is expected to be up to 592 million in the next two decades. DM causes various caridovascular complications. In additiion to that, in some patients, it may lead to ocular damage, kidney diseases, nerve damage and many more complications. This review highlighs the magnitude DM, its pathopysiotholgy and complications associated with patients with DM. It also give a picture of how dietary management as well as physical activities can help in the management of body gluecose. The paper highlights the pharmacological therapy of DM using different pharmacological drug classes. In addition, it also highlights how fixed dose combination of antidiabetic medication offer a means of simplifying dosing and timing schedules for number of medications, improve efficacy, lowers risk of adverse effect and are cost effective. In conclusion this paper highlights how a collaborative effort of a diabetologists, a dietician and a pharmacologist can have an effective management of DM in patients.

Keywords

Diabetes Mellitus, Fixed-dose Combination, Pharmacotherapy.
Subscription Login to verify subscription
User
Notifications
Font Size


  • World Health Organisation. Media centre, diabetes mellitus. 2018. Available from: URL: http://www.who.int/mediacentre/factsheets/fs138/en/.

  • American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care. 2014; 37 (Suppl 1): 81-90.

  • Abdelmoneim AS, Eurich DT, Gamble JM, et al. Use patterns of antidiabetic regimens by patients with type 2 diabetes. Canadian journal of diabetes. 2013; 37 (6): 394-400.

  • London Diabetes Centre. Worried about Diabetes? Available from: URL: https://londondiabetes.com/

  • Ozougwu JC, Obimba KC, Belonwu CD, et al. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. Journal of Physiology and Pathophysiology 2013; 4 (4): 46-57.

  • Baynes HW. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J diabetes metab. 2015; 6 (5): 1-9.

  • Li S, Guo S, He F, et al. Prevalence of diabetes mellitus and impaired fasting glucose, associated with risk factors in rural Kazakh adults in Xinjiang, China. International journal of environmental research and public health. 2015; 12 (1): 554-65.

  • Gupta M, Singh R, Lehl SS. Diabetes in India: a long way to go. International Journal of Scientific Reports. 2015; 1(1): 1-2.

  • Szablewski L. Role of immune system in type 1 diabetes mellitus pathogenesis. International immunopharmacology. 2014; 22 (1): 182-91.

  • Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409 (6818): 307.

  • Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The Lancet. 2017; 389(10085):2239-51.

  • Porte D, Schwartz MW. Diabetes Complications--Why Is Glucose Potentially Toxic?. Science. 1996; 272 (5262): 699.

  • Chien HY, Lee TP, Chen CY, et al. Circulating microRNA as a diagnostic marker in populations with type 2 diabetes mellitus and diabetic complications. Journal of the Chinese Medical Association. 2015; 78 (4): 204-11.

  • Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. The Lancet Neurology. 2006; 1;5 (1): 64-74.

  • Harper W, Clement M, Goldenberg R. et al. Pharmacological management of diabetes mellitus. Cannadian Journal of Diabetes. 2013; 37: 61-68.

  • Harvard Medical School. Eat Right, Reduce your Risk of Diabetes 2013; Available from: URL: https://www.health.harvard.edu/blog/the-data-are-in-eat-right-avoid-diabetes-2017010510936.

  • Knowler WC, Barrett-Connor E, Fowler SE. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England journal of medicine. 2002; 346 (6): 393-403.

  • Shimabukuro M, Zhou YT, Levi M. et al. Fatty acid-induced β cell apoptosis: a link between obesity and diabetes. Proceedings of the National Academy of Sciences. 1998; 95 (5): 2498-2502.

  • Bhathena SJ, Velasquez MT. Beneficial role of dietary phytoestrogens in obesity and diabetes. The American journal of clinical nutrition. 2002; 76 (6): 1191-1201.

  • Oju O, Oju OO, Adebowale F. et al. The Effect of Dietary Glycaemic Index on Glycaemia in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2018; 10 (3): 373.

  • Corbett E. 6-month treatment with a low-glycaemic diet was better than a high-fibre diet for glycaemic control in type 2 diabetes. Evidence-based medicine.2009; 14(3).

  • Campbell AP, Rains TM. Dietary protein is important in the practical management of prediabetes and type 2 diabetes. The Journal of nutrition. 2014; 145(1):164S-9S.

  • Campbell AP, Rains TM. Dietary Protein Is Important in the Practical Management of Prediabetes and Type 2 Diabetes. The Journal of Nutrition 2015; 164S–169S.

  • Boucher EA, Dunbar CM, Franz S, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 2013; 3821-3842.

  • Evert AB, Boucher JL, Cypress M, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes care. 2014; 37(sup l): S120-43.

  • Colditz G.A, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Annals of internal medicine 1995; 122(7): 481-486.

  • Micha R, Mozaffarian D. Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. Nature Reviews Endocrinology. 2009; 5(6): 335.

  • Tapsell LC, Gillen LJ, Patch CS, et al., Including walnuts in a low-fat/modified-fat diet improves HDL cholesterol-to-total cholesterol ratios in patients with type 2 diabetes. Diabetes care 2004; 27(12): 2777-2783.

  • Risérus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Progress in Lipid Research 2009; 44-51.

  • De Feo P, Di Loreto C, Ranchelli A, et al. Exercise and diabetes. Acta Biomed, 2006; 77 (Suppl 1): 14-17.

  • Asif, M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. Journal of Education and Health Promotion 2014; 1.

  • Skugor M. Diabetes Mellitus Treatment Published Cleveland Clinic Cetre for Contunuing Education 2018.

  • http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/diabetes-mellitus-treatment/.

  • American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2018; 41(suppl 1): 31–S59.

  • Kaul K, Apostolopoulou M, Roden M. Insulin resistance in type 1 diabetes mellitus. Metabolism.2015; 64(12): 1629–39

  • Jacobsen I.B, Henriksen J.E, Beck-Nielsen H. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol. 2009; 105(3):145–9.

  • Bailey C.J, Turner R.C. Metformin. N Engl J Med 1996; 334: 574–579.

  • Takahashi A, Nagashima K, Hamasaki A, et al. Sulfonylurea and glinide reduce insulin content, functional expression of KATP channels, and accelerate apoptotic β-cell death in the chronic phase. Diabetes research and clinical practice 2007; 77(3): 343-350.

  • Ahren, B. DPP-4 inhibitors. Best Practice & Research Clinical Endocrinology & Metabolism 2007; 21(4): 517-533.

  • Richter B, Bandeira‐Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2008; (2).

  • Payk SL, Drew RH, Smith JD, et al. Sulfonylurea prescribing patterns after the introduction of DPP-4 inhibitors and GLP-1 receptor agonists. Clinical therapeutics 2015; 37(7): 1477-1482.

  • U. S. Food and Drug Administration. FDA Drug Safety Product 2015.

  • Hollander P.A, Levy P, Fineman M.S, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes care, 2003; 26(3): 784-790.

  • Ryan G.J, Jobe L.J, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clinical therapeutics 2005; 27(10): 1500-1512.

  • Kern M, Klöting N, Mark M, et al. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism 2016; 65(2): 114-123.

  • Goldstein B.J, Pans, M, Rubin, CJ. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin therapeutics 2003; 25(3):890-903.

  • Haak T, Meinicke T, Jones R, et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double‐blind, placebo‐controlled study. Diabetes, Obesity and Metabolism 2012; 14(6): 565-574.

  • Blonde L, San Juan Z.T. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Advances in therapy. 2012 Jan 1; 29(1):1-3.

  • Bailey C.J, Day, C. Fixed‐dose single tablet antidiabetic combinations. Diabetes, Obesity and Metabolism 2009; 11(6): 527-533.

  • World Health Organisation. Essential medicines and health products. Adverse drug reactions monitoring 2018 http://www.who.int/medicines/areas/quality_safety/safety .

  • Egger M, Davey Smith G, Stettler C, et al. Risk of adverse effects of intensified treatment in insulin‐dependent diabetes mellitus: a meta‐analysis. Diab Med 1997; 14(11): 919-928.

  • Nisbet J.C, Sturtevant J.M, Prins JB. Metformin and serious adverse effects. Med journal of Aust 2004; 180(2):53


Abstract Views: 232

PDF Views: 0




  • Overview of Diabetes, Management, and Pharmacotherapy Updates a Review

Abstract Views: 232  |  PDF Views: 0

Authors

Sanusi Sani
Department of Pharmacology, Jamia Hamdard University, New Delhi, India
Zayyanu Shitu
Universiti Sultan Zainal Abidin, Gong Badak Campus, Kuala Terengganu, Malaysia
Faatimah Bah
Universiti Sultan Zainal Abidin, Gong Badak Campus, Kuala Terengganu, Malaysia
Tijjani Salihu Shinkafi
Department of Biochemistry, Usmanu Danfodio University, Sokoto, Nigeria
San San Oo
Universiti Sultan Zainal Abidin, Kota Campus, Kuala Terengganu, Malaysia
Zaw Aung
Universiti Sultan Zainal Abidin, Kota Campus, Kuala Terengganu, Malaysia

Abstract


Diabetes mellitus (DM) is disease of global concern. There were almost 4000 million diabetic people in 2013, and they number is expected to be up to 592 million in the next two decades. DM causes various caridovascular complications. In additiion to that, in some patients, it may lead to ocular damage, kidney diseases, nerve damage and many more complications. This review highlighs the magnitude DM, its pathopysiotholgy and complications associated with patients with DM. It also give a picture of how dietary management as well as physical activities can help in the management of body gluecose. The paper highlights the pharmacological therapy of DM using different pharmacological drug classes. In addition, it also highlights how fixed dose combination of antidiabetic medication offer a means of simplifying dosing and timing schedules for number of medications, improve efficacy, lowers risk of adverse effect and are cost effective. In conclusion this paper highlights how a collaborative effort of a diabetologists, a dietician and a pharmacologist can have an effective management of DM in patients.

Keywords


Diabetes Mellitus, Fixed-dose Combination, Pharmacotherapy.

References